Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis
Wineke Bakker,Monica Imbernon,Casper Gravesen Salinas,Daniela Herrera Moro Chao,Rim Hassouna,Chloe Morel,Claire Martin,Caroline Leger,Raphael G P Denis,Julien Castel,Andreas Peter,Martin Heni,Walter Maetzler,Heidi Solvang Nielsen,Manon Duquenne,Markus Schwaninger,Sofia Lundh,Wouter Frederic Johan Hogendorf,Giuseppe Gangarossa,Anna Secher,Jacob Hecksher-Sørensen,Thomas Åskov Pedersen,Vincent Prevot,Serge Luquet
DOI: https://doi.org/10.1016/j.celrep.2022.111698
2022-11-22
Abstract:Therapies based on glucagon-like peptide-1 (GLP-1) long-acting analogs and insulin are often used in the treatment of metabolic diseases. Both insulin and GLP-1 receptors are expressed in metabolically relevant brain regions, suggesting a cooperative action. However, the mechanisms underlying the synergistic actions of insulin and GLP-1R agonists remain elusive. In this study, we show that insulin-induced hypoglycemia enhances GLP-1R agonists entry in hypothalamic and area, leading to enhanced whole-body fat oxidation. Mechanistically, this phenomenon relies on the release of tanycyctic vascular endothelial growth factor A, which is selectively impaired after calorie-rich diet exposure. In humans, low blood glucose also correlates with enhanced blood-to-brain passage of insulin, suggesting that blood glucose gates the passage other energy-related signals in the brain. This study implies that the preventing hyperglycemia is important to harnessing the full benefit of GLP-1R agonist entry in the brain and action onto lipid mobilization and body weight loss.